Codexis Inc (CDXS)

Currency in USD
1.610
-0.100(-5.85%)
Closed·
1.620+0.010(+0.62%)
·
Unusual trading volume
CDXS is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
1.5351.940
52 wk Range
0.9583.870
Key Statistics
Prev. Close
1.71
Open
1.72
Day's Range
1.535-1.94
52 wk Range
0.958-3.87
Volume
6.08M
Average Vol. (3m)
2.12M
1-Year Change
-36.3636%
Book Value / Share
0.56
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
CDXS Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
6.583
Upside
+308.90%
Members' Sentiments
Bearish
Bullish
ProTips
RSI suggests the stock is in overbought territory

Codexis Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Neutral
Moving Averages
Buy

Codexis, Inc. provides technology solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop, enhance, and commercialize novel enzymes in the United States, Canada, Latin America, Europe, the Middle East, Africa, Australia, New Zealand, Southeast Asia, and China. The company develops its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. It has a license agreement with Aldevron LLC and Pfizer Inc. The company was incorporated in 2002 and is headquartered in Redwood City, California.

Codexis Inc SWOT Analysis


Market Momentum
Analyst targets range from $3 to $11, with potential $1B+ valuation if ECO Synthesis platform succeeds in capturing siRNA manufacturing market share
Collaborative Horizons
Explore Codexis's strategic partnerships, including plans for a major pharma collaboration and CDMO partnerships showcasing RNA ligases
Financial Fortitude
$60M cash cushion funds operations through 2026, aiming for positive cash flow, despite recent revenue decline and negative profit margins
Enzymatic Revolution
Codexis pivots to siRNA therapeutics manufacturing, potentially transforming the industry with its innovative ECO Synthesis platform
Read full SWOT analysis

Codexis Inc Earnings Call Summary for Q4/2025

  • Q4 2025 EPS of $0.11 beat forecast by 375%; revenue of $38.92M up 81% YoY, driven by $37.8M Merck technology transfer agreement.
  • Gross margin improved to 64% from 56% in 2024; R&D expenses fell 3.3% to $11.7M, SG&A decreased 13.8% to $11.2M in Q4.
  • Full-year 2025 net loss of $44M, improving 32.6% from prior year; stock rose 2.42% post-earnings despite trading 33% below 52-week high.
  • Guidance remains negative with Q1 2026 EPS forecast at -$0.11 and full-year 2026 at -$0.35; GMP facility expected operational by end of 2027.
  • CEO Nicols highlighted Merck partnership's strategic value; CFO Taylor emphasized cost management and product mix optimization driving margin gains.
Last Updated: 03/11/2026, 05:44 PM
Read Full Transcript

Compare CDXS to Peers and Sector

Metrics to compare
CDXS
Peers
Sector
Relationship
P/E Ratio
−3.2x−2.7x−0.5x
PEG Ratio
−0.080.000.00
Price / Book
2.8x1.5x2.6x
Price / LTM Sales
2.0x4.6x3.2x
Upside (Analyst Target)
309.4%152.1%53.2%
Fair Value Upside
Unlock21.0%7.6%Unlock

Analyst Ratings

5 Buy
2 Hold
0 Sell
Ratings:
7 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 6.583
(+308.90% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Stifel
Buy5.00+210.56%-MaintainMar 12, 2026
Cantor Fitzgerald
Buy11.00+583.23%11.00MaintainMar 12, 2026
Benchmark
Hold---MaintainAug 19, 2025
Stifel
Buy5.00+210.56%-MaintainAug 14, 2025
Cantor Fitzgerald
Buy11.00+583.23%-MaintainAug 14, 2025

Earnings

Latest Release
Mar 11, 2026
EPS / Forecast
0.11 / -0.04
Revenue / Forecast
38.92M / 33.55M
EPS Revisions
Last 90 days

CDXS Income Statement

People Also Watch

9.585
RDW
+1.11%
5.2600
SVRA
-1.13%
17.34
TNGX
+1.11%
13.200
EYPT
-5.92%

FAQ

What Is the Codexis (CDXS) Stock Price Today?

The Codexis stock price today is 1.610 USD.

What Stock Exchange Does Codexis Trade On?

Codexis is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Codexis?

The stock symbol for Codexis is "CDXS."

What Is the Codexis Market Cap?

As of today, Codexis market cap is 144.070M USD.

What Is Codexis's Earnings Per Share (TTM)?

The Codexis EPS (TTM) is -0.505.

When Is the Next Codexis Earnings Date?

Codexis will release its next earnings report on Apr 30, 2026.

From a Technical Analysis Perspective, Is CDXS a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Codexis Stock Split?

Codexis has split 0 times.

How Many Employees Does Codexis Have?

Codexis has 188 employees.

What is the current trading status of Codexis (CDXS)?

As of Mar 13, 2026, Codexis (CDXS) is trading at a price of 1.610 USD, with a previous close of 1.710 USD. The stock has fluctuated within a day range of 1.535 USD to 1.940 USD, while its 52-week range spans from 0.958 USD to 3.870 USD.

What Is Codexis (CDXS) Price Target According to Analysts?

The average 12-month price target for Codexis is 6.583 USD, with a high estimate of 11 USD and a low estimate of 2 USD. 5 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +308.90% Upside potential.

What Is the CDXS After Hours Price?

CDXS's last after hours stock price is 1.620 USD, the stock has decreased by 0.010, or 0.620%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.